Jan 20 (Reuters) - Moderna and Merck said on Tuesday their experimental personalized vaccine continued to cut the risk of ...
The five-year results come from a phase 2b study that tested intismeran autogene in combination with Merck’s Keytruda in ...
Moderna’s (MRNA) mRNA-based cancer therapy, intismeran autogene (mRNA-4157), with Merck’s (MRK) anti-PD-1 therapy, Keytruda, ...
The companies have an expansive clinical program for the mRNA neoantigen therapy intismeran autogene in combination with ...
A combination of intismeran autogene and Keytruda significantly prolonged recurrence-free survival in melanoma.
A personalized cancer treatment developed by Moderna Inc. and Merck & Co. helped prevent the recurrence of high-risk skin ...
USA-based mRNA vaccines company Moderna’s shares were flat in pre-market activity, as the company announced awaited new ...
Merck CEO Rob Davis expressed high confidence during the company’s J.P. Morgan presentation on Monday, revealing that the ...
Jan 20 () - Moderna and Merck said on Tuesday their experimental vaccine for a serious type of skin cancer, used in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback